富血小板血浆与皮质类固醇注射治疗肘部上髁炎和足底筋膜炎:更新的系统评价与Meta分析
该系统评价与Meta分析纳入20项前瞻性研究共1268例患者,比较富血小板血浆(PRP)与皮质类固醇(CS)注射治疗肘部上髁炎(EE)和足底筋膜炎(PF)的疗效。结果显示,EE长期疼痛改善PRP优于CS(效应量-1.3),PF长期功能改善PRP优于CS(效应量1.94),但证据等级多为低至中等。
要点
- EE长期疼痛改善PRP优于CS,效应量大但证据等级低。
- EE短期疼痛改善CS优于PRP,效应量中等,可能无临床意义。
- PF长期功能改善PRP优于CS,效应量大但证据等级低。
核心结论
- 在EE治疗中,PRP在长期疼痛改善方面较CS有统计学和临床意义的更优效果。
- 在PF治疗中,PRP在长期功能改善方面较CS有统计学和临床意义的更优效果。
- EE功能改善及PF疼痛和短期功能改善方面两组无显著差异,但证据质量低。
研究设计与样本
- 由独立评审者完成检索、筛选和偏倚风险评估。
主要发现
- EE长期疼痛:PRP较CS效应量为-1.3(95%CI,-1.9至-0.7),证据等级低。
- EE短期疼痛:CS较PRP效应量为0.56(95%CI,0.08-1.03),证据等级中等,可能无临床意义。
- PF长期功能(美国足踝外科协会评分):PRP较CS效应量为1.94(95%CI,0.61-3.28),证据等级低。
- EE功能改善及PF疼痛和短期功能改善两组无显著差异,证据质量低。
关键数值与推荐
- EE长期疼痛PRP vs CS效应量-1.3(95%CI,-1.9至-0.7)。
- EE短期疼痛CS vs PRP效应量0.56(95%CI,0.08-1.03)。
- PF长期功能PRP vs CS效应量1.94(95%CI,0.61-3.28)。
临床怎么用
- 对EE患者,可考虑PRP以获得更好的长期疼痛改善,但需告知证据等级低。
- 对PF患者,可考虑PRP以获得更好的长期功能改善,但需告知证据等级低。
- 短期疼痛控制方面CS对EE可能有效,但改善可能无临床意义。
局限性
- 纳入研究证据等级多为低至中等,结论可靠性受限。
- 原文未报告各研究具体异质性指标及发表偏倚评估结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platelet-rich plasma (PRP), as a promising alternative to traditional corticosteroid (CS), is now increasingly used in the treatment of elbow epicondylitis (EE) and plantar fasciitis (PF). To date, however, the synthesis of information on the clinical efficacy of PRP versus CS is limited with divergent conclusions. PURPOSE: To compare the clinical efficacy of PRP and CS injections in reducing pain and improving function in EE and PF. STUDY DESIGN: Systematic review and meta-analysis. METHODS: Online databases were searched from inception to October 2018 for prospective studies evaluating PRP versus CS injections for EE or PF. Independent reviewers undertook searches, screening, and risk-of-bias appraisals. The primary outcomes of interest were pain and function in both the short term (1-3 months) and the long term (≥6 months). RESULTS: Twenty trials with 1268 participants were included. For EE, PRP provides a statistically and clinically meaningful long-term improvement in pain, with a very large effect size of -1.3 (95% CI, -1.9 to -0.7) when compared with CS, but the evidence level was low. For EE, there was moderate evidence that CS provides a statistically meaningful improvement in pain in the short term, with a medium effect size of 0.56 (95% CI, 0.08-1.03) as compared with PRP; this improvement might not be clinically significant. For PF, there was low evidence that PRP provides a statistically and clinically meaningful long-term improvement in function (American Orthopedic Foot & Ankle Society score), with a very large effect size of 1.94 (95% CI, 0.61-3.28). There were no significant differences between the groups in improvement in function in EE and pain and short-term function in PF, but the quality of the evidence was low. CONCLUSION: The use of PRP yields statistically and clinically better improvement in long-term pain than does CS in the treatment of EE. The use of PRP yields statistically and clinically better long-term functional improvement than that of CS in the treatment of PF.
引用
- Huang K, Giddins G, Wu LD, et al. Platelet-Rich Plasma Versus Corticosteroid Injections in the Management of Elbow Epicondylitis and Plantar Fasciitis: An Updated Systematic Review and Meta-analysis. Am J Sports Med. 2019. PMID: 31821010. doi:10.1177/0363546519888450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。